MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated

Metastatic melanoma presents, in many cases, oncogenic mutations in BRAF, a MAPK involved in proliferation of tumour cells. BRAF inhibitors, used as therapy in patients with these mutations, often lead to tumour resistance and, thus, the use of MEK inhibitors was introduced in clinics. BRAFi/MEKi, a...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Borrego, Silvia, Campos-Silva, Carmen, Sandúa, Amaia, Camino, Tamara, Téllez-Pérez, Lucía, Alegre, Estibaliz, Beneitez, Alexandra, Jara-Acevedo, Ricardo, Paschen, Annette, Pardo, María, González, Álvaro, Valés-Gómez, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884675/
https://www.ncbi.nlm.nih.gov/pubmed/36726591
http://dx.doi.org/10.3389/fcell.2022.1055288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884675/
https://www.ncbi.nlm.nih.gov/pubmed/36726591
http://dx.doi.org/10.3389/fcell.2022.1055288

Ejemplares similares